Fundraising FoxNeurotronic
1 known investors
Find your way into Neurotronic
Sign up to see every warm intro you have to Neurotronic
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurotronic team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neurotronic is developing Neuviant Multi-organ Denervation (MDN), an investigational catheter-based therapy that delivers ethanol to overactive sympathetic nerves near the kidneys and liver to lower blood sugar and blood pressure. It targets patients with type 2 diabetes and hypertension that remain uncontrolled despite lifestyle changes and medication, and is being evaluated in the U.S. TRIUMPH clinical study.</parameter> <parameter name="sector_codes">["medtech", "healthtech", "biotech"]
Investors · 1
Frequently asked questions
- What does Neurotronic do?
- Neurotronic is developing Neuviant Multi-organ Denervation (MDN), an investigational catheter-based therapy that delivers ethanol to overactive sympathetic nerves near the kidneys and liver to lower blood sugar and blood pressure. It targets patients with type 2 diabetes and hypertension that remain uncontrolled despite lifestyle changes and medication, and is being evaluated in the U.S. TRIUMPH clinical study.</parameter> <parameter name="sector_codes">["medtech", "healthtech", "biotech"]
- Who are Neurotronic's investors?
- Neurotronic's investors include HM Venture Partners.